A Multicenter, Open-Label, Phase 2 Trial to Evaluate the Safety and Activity of Efgartigimod (ARGX-113) in Adult Patients with Primary Immune Thrombocytopenia - ARGX-113-1804

Argenx BVBA0 sites15 target enrollmentFebruary 6, 2020

ConditionsPrimary Immune Thrombocytopenia MedDRA version: 20.1Level: LLTClassification code 10074678Term: Primary immune thrombocytopenic purpuraSystem Organ Class: 100000004851 Therapeutic area: Body processes [G] - Immune system processes [G12]

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Primary Immune Thrombocytopenia
Sponsor: Argenx BVBA
Enrollment: 15
Status: Active, not recruiting
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

February 6, 2020

End Date

TBD

Last Updated

5 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

Argenx BVBA

Eligibility Criteria

Inclusion Criteria

•1\. Ability to understand the requirements of the trial, to provide written informed consent (or patient’s legally authorised representative) (including consent for the use and disclosure of research\-related health information), and to comply with the trial protocol procedures (including required trial visits).
•2\. Male or female patients aged \=18 years.
•3\. Confirmed ITP diagnosis, at least 3 months before Baseline and according to the American Society of Haematology Criteria 2011, and no known other etiology for thrombocytopenia.
•4\. Diagnosis supported by a response to a prior ITP therapy, in the opinion of the investigator.
•5\. Mean platelet count of \<30×10?/L (and no single platelet count of \>35×10?/L) from 3 qualifying counts, 2 during the screening period and the pre\-dose platelet count at Visit 1\. The 3 platelet counts must be over the course of 7 to 14 days, with at least 2 days between any 2 counts.
•6\. Patients receiving permitted concurrent ITP treatments at Baseline, must have been stable in dose and frequency for at least 4 weeks prior to Baseline. Permitted concurrent ITP medications include oral corticosteroids, oral immunosuppressants, and/or eltrombopag. Patients not receiving concurrent ITP therapy are also eligible for the trial if they have not received prior ITP therapy for at least 4 weeks prior to Baseline.
•7\. Women of childbearing potential must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at Baseline prior to infusion. Women of childbearing potential are defined as all female patients unless they are post\-menopausal (defined by continuous amenorrhea) for at least 1 year with a follicle\-stimulating hormone (FSH) of \>40 IU/L or are surgically sterile (i.e. women who had a hysterectomy, both ovaries surgically removed, or have documented tubal ligation or any other documented permanent female sterilisation procedure). Follicle\-stimulating hormone can be used to confirm post\-menopausal status in amenorrheic patients not on hormonal replacement therapy if the value is within the post\-menopausal range per the laboratory.
•8\. Women of childbearing potential should use a highly effective method of contraception (i.e. pregnancy rate of less than 1% per year) during the trial and for 90 days after the last administration of the IMP. They must be on a stable regimen, for at least 1 month, of combined estrogen and progestogen hormonal contraception with inhibition of ovulation, progestogen\-only hormonal contraception associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone\-releasing system, bilateral tubal occlusion, vasectomised partner, or agree upon continuous abstinence from heterosexual sexual contact. Sexual abstinence is only allowable if it is the preferred and usual lifestyle of the patient. Periodic abstinence (calendar, symptothermal, post\-ovulation methods) is not acceptable.
•9\. Non\-sterilised male patients who are sexually active with a female partner of childbearing potential must use effective double contraception, of which 1 method must be a barrier method and the other another barrier method or highly effective form of contraception as described above for women of childbearing potential (e.g. condom with spermicidal cream or jelly, 1 hormonal plus 1 barrier method, IUD plus 1 barrier method, or 2 simultaneous barrier methods). Male patients practicing true sexual abstinence (when this is in line with the preferred and usua

Exclusion Criteria

•1\. ITP associated with another condition, e.g. lymphoma, chronic lymphocytic leukemia, viral infection, autoimmune disorders, thyroid disease, human immunodeficiency virus (HIV), hepatitis, induced or alloimmune thrombocytopenia, or thrombocytopenia associated with myeloid dysplasia.
•2\. Symptoms of, or receiving treatment for, systemic lupus erythematosus, antiphospholipid antibody syndrome or any other clinically documented autoimmune disease other than ITP.
•3\. Use of anticoagulants, or any drug with antiplatelet effect (e.g. acetylsalicylic acid \[aspirin] or other salicylate containing medications, cyclooxygenase inhibitors, adenosine diphosphate receptor inhibitors, phosphodiesterase inhibitors, glycoprotein IIB/IIIA inhibitors, adenosine reuptake inhibitors, thromboxane inhibitors, antimalarials, and prostacyclin) within 4 weeks prior to Baseline.
•4\. Use of any blood support or transfusion within 4 weeks prior to Baseline.
•5\. Use of IVIg, SC or intramuscular route, or PLEX, 4 weeks prior to Baseline.
•6\. Use of rituximab within 6 months prior to Baseline.
•7\. Use of romiplostim within 4 weeks prior to Baseline.
•8\. Use of fostamatinib within 4 weeks prior to Baseline.
•9\. Undergone splenectomy less than 4 weeks prior to Baseline.
•10\. Use of any other biological therapy or investigational drug than those previously indicated within 3 months or 5 half\-lives of the drug (whichever is longer) prior to Baseline.